RhumbLine Advisers
HRMY icon

RhumbLine Advisers’s Harmony Biosciences HRMY Stock Holding History

RhumbLine Advisers’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.75M Sell
102,915
-14,090
-12% -$444K ﹤0.01% 1608
2026
Q1 		$3.28M Buy
117,005
+77
+0.1% +$2.52K ﹤0.01% 1607
2025
Q4 		$4.38M Sell
116,928
-6,061
-5% -$199K ﹤0.01% 1465
2025
Q3 		$3.39M Buy
122,989
+3,788
+3% +$130K ﹤0.01% 1622
2025
Q2 		$3.77M Buy
119,201
+10,128
+9% +$326K ﹤0.01% 1563
2025
Q1 		$3.62M Buy
109,073
+485
+0.4% +$17.4K ﹤0.01% 1517
2024
Q4 		$3.74M Buy
108,588
+16,537
+18% +$568K ﹤0.01% 1563
2024
Q3 		$3.68M Sell
92,051
-8,643
-9% -$304K ﹤0.01% 1584
2024
Q2 		$3.04M Sell
100,694
-3,421
-3% -$103K ﹤0.01% 1667
2024
Q1 		$3.5M Buy
104,115
+3,570
+4% +$115K ﹤0.01% 1605
2023
Q4 		$3.25M Sell
100,545
-1,836
-2% -$51.2K ﹤0.01% 1657
2023
Q3 		$3.36M Buy
102,381
+7,515
+8% +$261K ﹤0.01% 1578
2023
Q2 		$3.34M Buy
94,866
+10,424
+12% +$360K ﹤0.01% 1622
2023
Q1 		$2.76M Buy
84,442
+4,557
+6% +$208K ﹤0.01% 1643
2022
Q4 		$4.4M Buy
79,885
+413
+0.5% +$22.7K 0.01% 1353
2022
Q3 		$3.52M Buy
79,472
+13,075
+20% +$638K 0.01% 1437
2022
Q2 		$3.24M Buy
66,397
+7,106
+12% +$320K ﹤0.01% 1495
2022
Q1 		$2.88M Buy
59,291
+5,702
+11% +$233K ﹤0.01% 1620
2021
Q4 		$2.29M Buy
53,589
+33,492
+167% +$1.33M ﹤0.01% 1806
2021
Q3 		$770K Buy
20,097
+1,097
+6% +$35.3K ﹤0.01% 2347
2021
Q2 		$536K Buy
+19,000
New +$570K ﹤0.01% 2531

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RhumbLine Advisers's HRMY Position: Q2 2026 in Review

RhumbLine Advisers reduced its Harmony Biosciences (HRMY) stake by 12% in Q2 2026, selling an estimated $444K and leaving 102,915 shares worth $3.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1608.

RhumbLine Advisers first reported a position in HRMY in Q2 2021 and has held it in 21 quarters since. The position peaked at $4.4M in Q4 2022. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • RhumbLine Advisers held 102,915 shares of Harmony Biosciences worth $3.75M as of Q2 2026.
  • RhumbLine Advisers sold 14,090 Harmony Biosciences shares in Q2 2026, an estimated $444K.
  • Harmony Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1608 holding.
  • RhumbLine Advisers first reported a position in Harmony Biosciences in Q2 2021 and has held it in 21 quarters since.
  • RhumbLine Advisers's Harmony Biosciences position peaked at $4.4M in Q4 2022.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.